A U.S. Food and Drug Administration advisory panel voted against recommending AstraZeneca's experimental breast-cancer drug camizestrant on May 1, 2026 [4].
The decision represents a significant setback for the British pharmaceutical group, as the panel's skepticism regarding the drug's efficacy impacts both the product's path to market and the company's valuation.
Panel members said the clinical trial design did not sufficiently demonstrate that switching to camizestrant early in treatment would improve long-term survival for patients [1]. The committee reached a six-three vote against the drug [3].
Following the announcement, AstraZeneca's share price declined. Reports on the exact dip vary between 1.9% [1] and 2.5% [2].
While some reports indicate the vote occurred on April 30, 2026 [5], the results were widely reported on May 1 [4]. The panel's focus remained on whether the patient benefit justified the drug's use over existing treatments.
Camizestrant was developed as a potential candidate to treat breast cancer, but the FDA advisory committee said the study's design lacked the necessary evidence to support a recommendation for approval [1].
AstraZeneca has not provided a public response to the specific vote count or the trial design criticisms in the immediate aftermath of the panel's decision.
“The FDA advisory committee vote count was 6-3 against the drug.”
The FDA advisory panel's rejection suggests that the current clinical data for camizestrant is insufficient to prove a survival advantage over existing therapies. Because the FDA often follows these recommendations, AstraZeneca may need to redesign its trials or provide more robust data to secure regulatory approval, delaying the drug's entry into the U.S. market.
